Shionogi & Co., Ltd.
【Shionogi & Co., Ltd.】2026 Financial Results Supplemental Materials | Sales of JPY 499.7 billion (Up 14.0% Year-over-Year)
Shionogi & Co., Ltd.'s fiscal year ending March 2026 reported sales of JPY 499.7 billion (up 14.0% YoY), operating profit is unspecified, net income increased by 21.5% to JPY 205.9 billion. Overseas sales have also grown significantly.
Key Figures
- Net Sales: JPY 499.7 billion (Up 14.0% YoY)
- Net Income: JPY 205.9 billion (21.5% increase)
- Overseas Subsidiaries/Export Sales: JPY 65 billion (9.9% increase)
AI要約
Performance Overview
Shionogi & Co., Ltd.'s consolidated net sales for the fiscal year ending March 2026 reached JPY 499.7 billion, representing a 14.0% increase YoY, with overseas sales also robust at JPY 65 billion. Although detailed figures for gross profit and operating profit are not provided, net income rose by 21.5% to JPY 205.9 billion, indicating improved profitability. Research and development expenses and sales, general and administrative expenses have increased, reflecting ongoing investments in new drugs and vaccines. Future outlooks and forecast achievement ratios are also presented.
Impact on Shareholders and Future Outlook
With increases in sales and net income, shareholder returns and dividend increases are expected. Growth prospects are supported by overseas expansion and development of new drugs. The company's financial position remains solid; although share buyback and capital policy movements are not detailed, future business strategies are attracting attention.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
